Previous 10 | Next 10 |
CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced that Charles Wilson, Ph.D., President and Chief Executive Officer, will present at ...
The following slide deck was published by Unum Therapeutics Inc. in conjunction with this Read more ...
Unum Therapeutics Inc. (UMRX) Q2 2019 Earnings Conference Call August 12, 2019 16:30 ET Corporate Participants Chuck Wilson - Chief Executive Officer Jessica Sachs - Chief Medical Officer Seth Ettenberg - Chief Scientific Officer Matt Osborne - Chief Financial Officer Confer...
Unum Therapeutics (NASDAQ: UMRX ): Q2 GAAP EPS of -$0.34 beats by $0.07 . More news on: Unum Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
- Updated results from Phase 1 trial with ACTR707 in combination with rituximab in adults with relapsed/refractory non-Hodgkin lymphoma confirms the clinical activity achieved in previous cohorts with no adverse events of cytokine release syndrome or severe neurotoxicity – ...
CAMBRIDGE, Mass., Aug. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (Nasdaq: UMRX), a biopharmaceutical company focused on developing potentially curative cellular immunotherapies through its ACTR and BOXR platforms, today announced that the company will host a conference call and li...
CAMBRIDGE, Mass., July 29, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, ACTR and BOXR, today announced the app...
CAMBRIDGE, Mass., July 17, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that Charles Wilson, P...
Thinly traded nano cap Unum Therapeutics (NASDAQ: UMRX ) slumps 23% after hours on light volume in reaction to a clinical hold placed by the FDA on its Phase 1 clinical trial evaluating ACTR087, combined with Roche's Rituxan (rituximab) after lymphodepleting chemo, in patient...
CAMBRIDGE, Mass., July 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of cellular immunotherapies to treat cancer based on its novel T cell technology platforms, today announced that the U.S. Food and...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass. and BOULDER, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced Andrew Robbins, Chief Executive Officer and President, wil...
Unum Therapeutics Announces Company Name Change to Cogent Biosciences, Highlights Recent Scientific and Operational Progress Cogent Biosciences is focused on the design of rational precision therapies to improve the lives of patients Company on track to advance CGT9486 into ...
SOTIO will establish a T cell therapy R&D Center of Excellence in Cambridge, Massachusetts Unum’s former chief technology officer Geoff Hodge to join SOTIO to lead BOXR development team and all research and development of the next generation T cell therapies Lead progra...